Biblio Discovery — Demo Discovery Service

91 results for "Burisch, Johan"

Showing 81–91 · 0.87 seconds · RSS

  1. Journal Article Full text

    Diagnostics of Autoimmune Hepatitis Enabled by Non‐Invasive Clinical Proteomics

    Jensen, Anne‐Sofie Houlberg; Ytting, Henriette; Nielsen, Annelaura Bach et al.

    Aliment Pharmacol Ther · 2025 · English · PubMed Central

    BACKGROUND: Autoimmune hepatitis (AIH) may be difficult to diagnose and distinguish clinically and biochemically from other chronic liver diseases like metabolic dysfunction‐associated steatotic liver disease (MASLD). AIMS: To identify pathways involved in the pathogenesis and identify…

  2. Journal Article Full text

    Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey

    Ellul, Pierre; Revés, Joana; Abreu, Bárbara et al.

    J Crohns Colitis · 2022 · English · PubMed Central

    INTRODUCTION: Anti-SARS-CoV-2 vaccines clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease (IBD). We aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients, patients’ concerns and side-effect profile of the…

  3. Journal Article Full text

    The CROCO (CROhn’s Disease COhort Study) – study design and protocol

    Revés, Joana; Buisson, Anthony; Burisch, Johan et al.

    Ther Adv Gastroenterol · 2025 · English · PubMed Central

    BACKGROUND: Crohn’s disease (CD) is a chronic, relapsing and remitting inflammatory bowel disease that can be associated with significant bowel damage and disability. The Lémann Index (LI) is a validated tool for measuring cumulative bowel damage in CD patients through a comprehensive assessment of…

  4. Journal Article Full text

    Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease

    Salihovic, Samira; Nyström, Niklas; Mathisen, Charlotte Bache-Wiig et al.

    Nat Commun · 2024 · English · PubMed Central

    Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-naïve pediatric patients and validating findings in an…

  5. Journal Article Full text

    Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis

    de Frias Gomes, Catarina Geraldes; de Almeida, Alexandra Sofia Ribeiro; Mendes, Catarina Callé Lucas et al.

    Inflamm Bowel Dis · 2021 · English · PubMed Central

    BACKGROUND: The Montreal classification categorizes patients with ulcerative colitis (UC) based on their macroscopic disease extent. Independent of endoscopic extent, biopsies through all colonic segments should be retrieved during index colonoscopy. However, the prognostic value of histological…

  6. Journal Article Full text

    Influence of Genetics, Immunity and the Microbiome on the Prognosis of Inflammatory Bowel Disease (IBD Prognosis Study): the protocol for a Copenhagen IBD Inception Cohort Study

    Attauabi, Mohamed; Madsen, Gorm Roager; Bendtsen, Flemming et al.

    BMJ Open · 2022 · English · PubMed Central

    INTRODUCTION: Inflammatory bowel diseases (IBD), encompassing Crohn’s disease and ulcerative colitis, are chronic, inflammatory diseases of the gastrointestinal tract. We have initiated a Danish population-based inception cohort study aiming to investigate the underlying mechanisms for the…

  7. Journal Article Full text

    Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

    Albshesh, Ahmad; Taylor, Joshua; Savarino, Edoardo V. et al.

    J Clin Med · 2021 · English · PubMed Central

    Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and…

  8. Journal Article Full text

    The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study

    Burisch, Johan; Bergemalm, Daniel; Halfvarson, Jonas et al.

    United European Gastroenterol J · 2020 · English · PubMed Central

    BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn’s disease is in sharp contrast to its widespread use in clinical practice. AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn’s disease…

  9. Journal Article Full text

    Global evolution of inflammatory bowel disease across epidemiologic stages

    Hracs, Lindsay; Windsor, Joseph W.; Gorospe, Julia et al.

    Nature · 2025 · English · PubMed Central

    During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania(1). At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin…

  10. Journal Article Full text

    Cohort profile: Copenhagen Hospital Biobank-chronic inflammatory disease—inflammatory bowel disease (CHB-CID:IBD) genetic cohort

    Darbani, Behrooz; Brodersen, Thorsten; Liljensøe, Anette et al.

    Eur J Epidemiol · 2025 · English · PubMed Central

    The Copenhagen Hospital Biobank-chronic inflammatory disease—inflammatory bowel disease (CHB-CID: IBD) cohort contributes to genetic research in inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Of the 327,084 enrolled and genotyped individuals in the cohort, 10,626 have…